

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Molnupiravir Capsule Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.
Menuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION**GHS classification of chemical product**

Specific target organ toxicity - : Category 1 (Gastrointestinal tract)
repeated exposure (Oral)

GHS label elements

Hazard pictograms



Signal word

: Danger

Hazard statements

: H372 Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.

Precautionary statements

: **Prevention:**
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:

P314 Get medical advice/ attention if you feel unwell.

Disposal:

Molnupiravir Capsule Formulation

Version 12.0	Revision Date: 2025/06/20	SDS Number: 6199211-00017	Date of last issue: 2025/04/14 Date of first issue: 2020/08/24
-----------------	------------------------------	------------------------------	---

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed : May form explosive dust-air mixture during processing, handling or other means.
Dust contact with the eyes can lead to mechanical irritation.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	>= 80 - < 90	
Molnupiravir	2492423-29-5	>= 70 - < 80	-

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes damage to organs through prolonged or repeated exposure if swallowed.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Molnupiravir Capsule Formulation

Version 12.0	Revision Date: 2025/06/20	SDS Number: 6199211-00017	Date of last issue: 2025/04/14 Date of first issue: 2020/08/24
-----------------	------------------------------	------------------------------	---

- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Molnupiravir Capsule Formulation

Version 12.0	Revision Date: 2025/06/20	SDS Number: 6199211-00017	Date of last issue: 2025/04/14 Date of first issue: 2020/08/24
-----------------	------------------------------	------------------------------	---

7. HANDLING AND STORAGE**Handling**

- | | |
|-------------------------|--|
| Technical measures | : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : Use only with adequate ventilation. |
| Advice on safe handling | : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Avoidance of contact | : Oxidizing agents |
| Hygiene measures | : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

Storage

- | | |
|-----------------------------|--|
| Conditions for safe storage | : Keep in properly labelled containers.
Store in accordance with the particular national regulations. |
| Materials to avoid | : Do not store with the following product types:
Strong oxidizing agents |
| Packaging material | : Unsuitable material: None known. |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible con-	Basis

Molnupiravir Capsule Formulation

Version 12.0 Revision Date: 2025/06/20 SDS Number: 6199211-00017 Date of last issue: 2025/04/14
 Date of first issue: 2020/08/24

			centration	
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Molnupiravir	2492423-29-5	TWA	20 µg/m3 (OEB 3)	Internal
		Wipe limit	200 µg/100cm2	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Molnupiravir Capsule Formulation

Version 12.0	Revision Date: 2025/06/20	SDS Number: 6199211-00017	Date of last issue: 2025/04/14 Date of first issue: 2020/08/24
-----------------	------------------------------	------------------------------	---

Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Lower explosion limit and upper explosion limit / flammability limit		
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Decomposition temperature	:	No data available
pH	:	No data available
Evaporation rate	:	Not applicable
Auto-ignition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Density and / or relative density		
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Molnupiravir:

Acute oral toxicity	:	LD0 (Rat): 2,000 mg/kg LD0 (Dog): 2,000 mg/kg
---------------------	---	--

Skin corrosion/irritation

Not classified based on available information.

Components:**Molnupiravir:**

Species	:	reconstructed human epidermis (RhE)
Method	:	EpiDerm
Result	:	Mild skin irritation

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Molnupiravir:**

Species	:	Bovine cornea
Result	:	No eye irritation
Method	:	Bovine cornea (BCOP)

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Molnupiravir:

Genotoxicity in vitro	:	Test Type: Ames test Result: positive Test Type: Micronucleus test Test system: human lymphoblastoid cells Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Species: Rat
Cell type: Bone marrow
Result: equivocal

Test Type: Mutagenicity (in vivo mammalian bone-marrow
cytogenetic test, chromosomal analysis)
Species: Transgenic rat
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Molnupiravir:

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: > 200 mg/kg body weight
Symptoms: Effects on embryofoetal and postnatal development
Result: No effects on fertility and early embryonic development were detected.
Remarks: Not classified due to data which are conclusive although insufficient for classification.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.

Components:**Molnupiravir:**

Exposure routes	: Oral
Target Organs	: Gastrointestinal tract
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Molnupiravir:

Species	: Rat
LOAEL	: 2,000 mg/kg
Exposure time	: 7 d
Target Organs	: Stomach

Species	: Dog
LOAEL	: 300 mg/kg
Exposure time	: 7 d
Target Organs	: Gastrointestinal tract
Symptoms	: tachycardia, decreased activity, decrease in appetite, Diarrhoea, Vomiting

Species	: Rat
NOAEL	: 500 mg/kg
Exposure time	: 28 d

Species	: Dog
NOAEL	: 6 mg/kg
LOAEL	: 17 mg/kg
Exposure time	: 28 d
Target Organs	: Gastrointestinal tract
Symptoms	: decreased activity, Gastrointestinal tract damage, decrease in appetite

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Molnupiravir:**

General Information : Symptoms: Headache, Gastrointestinal disturbance
Remarks: The most common side effects are:

Symptoms: Back pain

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Molnupiravir:

Toxicity to algae/aquatic plants : EC10 (*Raphidocelis subcapitata* (freshwater green alga)): 89 mg/l
End point: Growth
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : EC10 (*Pimephales promelas* (fathead minnow)): 5.8 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : EC10 (*Daphnia magna* (Water flea)): > 8.8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC10: 143.1 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition of activated sludge
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Molnupiravir:Biodegradability : Result: Readily biodegradable.
Biodegradation: 81 %
Exposure time: 28 d
Method: OECD Test Guideline 314**Bioaccumulative potential****Components:****Molnupiravir:**Partition coefficient: n- : log Pow: -0.534
octanol/water pH: 7**Mobility in soil****Components:****Molnupiravir:**Distribution among environ- : OECD Test Guideline 106
mental compartments log Koc: 1.45**Hazardous to the ozone layer**

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : Not applicable

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Not applicable

Substances Subject to be Indicated Names

Not applicable

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
12.0	2025/06/20	6199211-00017	Date of first issue: 2020/08/24

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN